Nephrology Medical News about sorafenib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET
Medical Oncology, 09/24/09

Negrier S et al. – Sorafenib demonstrated a consistent, significant clinical benefit against advanced renal cell carcinoma, with a twofold improvement in progression–free survival and disease control rate, with similar toxicities in patients with or without prior cytokine treatment.

<< Previous
Frequency and Risk Factors for Posttransplant Diabetes Mellitus...

Next >>
Role of Resistive Index Measurement in Diagnosis of Acute...

Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09 Relevance Score: 96%

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety
Hepatology, 11/02/09 Relevance Score: 87%

Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Annals of Oncology, 10/29/09 Relevance Score: 87%

Glucose-Regulated Protein 78 Is a Novel Contributor to Acquisition of Resistance to Sorafenib in Hepatocellular Carcinoma
Annals of Surgical Oncology, 10/20/09 Relevance Score: 87%

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
European Journal of Endocrinology, 10/06/09 Relevance Score: 87%